Herpes simplex: Evolving concepts

Journal of the American Academy of Dermatology

Volumn 35, Issue 4, 1996, Pages 503-520

  Pereira, Frederick A ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NUCLEOSIDE ANALOG; PENCICLOVIR;

ANTIVIRAL ACTIVITY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; PRIORITY JOURNAL; REVIEW; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSMISSION;

EID: 0030470940     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90670-2     Document Type: Article

References (182)

1. Ho DY. Herpes simplex virus latency: molecular aspects. Prog Med Virol 1992;39:76-115.
2. Steiner I, Kennedy PGE. Molecular biology of herpes simplex virus type 1 latency in the nervous system. Mol Neurobiol 1993;7:137-59.
3. Roizman B, Sears AE. Herpes simplex viruses and their replication. In: Fields BN, Knipe DM, editors. Virology. New York: Raven Press, 1990:1795-841.
4. Poffenberger KL, Tabares E, Roizman B. Characterization of a viable, non-inverting herpes simplex virus 1 genome derived by insertion of sequences at the L-S component junction. Proc Natl Acad Sci U S A 1983; 80:2690-4.
5. Wu TJ, Monokian G, Mark DF, et al. Transcriptional activation by herpes simplex virus type 1 VP16 in vitro and its inhibition by oligopeptides. Mol Cell Biol 1994; 14:3484-93.
6. Kwong AD, Frenkel N. Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNA's. Proc Natl Acad Sci U S A 1987;84:1926-30.
7. Kwong AD, Kruper JA, Frenkel N. Herpes simplex virion host shutoff function. J Virol 1988;62:912-21.
8. Ghiasi H, Kaiwar R, Nesburn AB, et al. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J Virol 1994;68:2118-26.
9. Hutchinson L, Browne H, Wargent V, et al. A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH. J Virol 1992;66:2240-50.
10. Hutchinson L, Goldsmith K, Snoddy D, et al. Identification and characterization of a novel herpes simplex virus glycoprotein, gK, involved in cell fusion. J Virol 1992; 66:5603-9.
11. Banfield DW, Leduc Y, Esford L, et al. Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection. Virology 1995; 208:531-9.
12. Newcomb WW, Brown JC. Induced extrusion of DNA from the capsid of herpes simplex virus type 1. J Virol 1994;68:433-40.
13. Batterson W, Roizman B. Characterization of the herpes simplex virion-associated factor responsible for the induction of α genes. J Virol 1983;46:371-7.
14. Zhu Z, Shaffer PA. Intracellular localization of the herpes simplex type 1 major transcriptional regulatory protein, ICP4, is affected by ICP27. J Virol 1995;69:49-59.
15. Holland LE, Anderson KP, Shipman C, et al. Viral DNA synthesis is required for the efficient expression of specific herpes simplex virus type 1 mRNA species. Virology 1980;101:10-24.
16. Jacob RJ, Morse LS, Roisman B. Anatomy of herpes simplex virus DNA. XIII. Accumulation of head to tail concatamers in nuclei of infected cells and their role in the generation of the four isomeric arrangements of viral DNA. J Virol 1979;29:448-57.
17. Deiss LP, Frenkel N. Herpes simplex virus amplicon: cleavage of concatameric DNA is linked to packaging and involves amplification of the terminally reiterated a sequence. J Virol 1986;57:933-41.
18. Stevens JG, Cook ML. Latent herpes simplex virus in spinal ganglia of mice. Science 1971;173:843-5.
19. Baringer JR, Swoveland P. Recovery of herpes simplex virus from human trigeminal ganglia. N Engl J Med 1973; 288:648-50.
20. Bastian RR, Rabson AS, Yee CL, et al. Herpes virus hominis: isolation from human trigeminal ganglia. Science 1972;178:306-7.
21. Warren KG, Brown SM, Wroblewska Z, et al. Isolation of latent herpes simplex virus from the superior cervical and vagus ganglions of human beings. N Engl J Med 1978;298:1068-70.
22. Warren KG, Gilden DH, Brown SM, et al. Isolation of latent herpes simplex virus from human trigeminal ganglia including ganglia from one patient with multiple sclerosis. Lancet 1977;2:637-9.
23. Plummer G. Isolation of herpesvirus from the trigeminal ganglia of man, monkeys and cats. J Infect Dis 1973; 128:345-8.
24. Steiner I, Spivack JG, Deshmane SL, et al. A herpes simplex virus type 1 mutant containing a non-transinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J Virol 1990;64: 1630-8.
25. Efstathiou S, Kemp S, Darby G, et al. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol 1989;70:869-79.
26. Sadowski I, Ma J, Triezemberg J, et al. GAL4-VP16 is an unusually potent transcriptional activator. Nature (London) 1988;335:563-4.
27. Douville P, Hagmann M, Georgiev O, et al. Positive and negative regulation at the herpes simplex virus ICP4 and ICPO TAATGARAT motifs. Virology 1995;207:107-16.
28. Kristie T, Sharp PA. Interactions of the Oct-1 POU sub-domains with specific DNA sequences and with the HSV α-trans-activator protein. Genes Dev 1990;4:2383-96.
29. Cleary MA, Herr W. Mechanisms for flexibility in DNA sequence recognition and VP-16-induced complex formation by the Oct-1 POU domain. Mol Cell Biol 1995; 15:2090-100.
30. Lilly crop KA, Estridge JK, Latchman DS. The octamer-binding protein Oct-2 inhibits transactivation of the herpes simplex virus immediate-early genes by the virion protein Vmw65. Virology 1993;196:888-91.
31. Lillycrop KA, Dent CL, Wheatley SC, et al. The octamer-binding protein Oct-2 represses HSV immediate-early genes in cell Unes derived from latently infectable sensory neurons. Neuron 1991;7:381-90.
32. Lillycrop KA, Dawson SJ, Estridge JK, et al. Repression of a herpes simplex virus immediate-early promoter by the Oct-2 transcription factor is dependent on an inhibitory region at the N terminus of the protein. Mol Cell Biol 1994;14:7633-42.
33. Lillycrop KA, Estridge JK, Lachman DS. Functional interaction between different isoforms of the Oct-2 transcription factor expressed in neuronal cells. Biochem J 1994;298(pt 1):245-8.
34. Lillycrop KA, Howard MK, Estridge JK, et al. Inhibition of herpes simplex virus infection by ectopic expression of neuronal splice variants of the Oct-2 transcription factor. Nucleic Acids Res 1994;22:815-20.
35. Lillycrop KA, Liv Y-Z, Theil T, et al. Activation of the herpes simplex virus immediate-early gene promoters by neuronally expressed POU family transcription factors. Biochem J 1995;307:581-4.
36. Morris PJ, Thiel T, Ring CJ, et al. The opposite and antagonistic effects of the closely related POU family transcription factors Brn-3a and Brn-3b on the activity of a target promoter are dependent on differences in the POU domain. Mol Cell Biol 1994;14:6907-14.
37. Fraser NW, Valyi-Nagy T. Viral, neuronal and immune factors which may influence herpes simplex virus (HSV) latency and reactivation. Microb Pathog 1993;15:83-91.
38. Wilcox CL, Johnson EM. Characterization of nerve growth factor-dependent herpes simplex virus latency in neurons in vitro. J Virol 1988;62:393-9.
39. Wilcox CL, Smith RL, Freed CR, et al. Nerve growth factor-dependence of herpes simplex virus latency in peripheral sympathetic and sensory neurons in vitro. J Neurosci 1990;10:1268-75.
40. Wood JN, Lillycrop KA, Dent CL, et al. Regulation of expression of the neuronal POU protein Oct-2 by nerve growth factor. J Biol Chem 1992;267:17787-91.
41. Valyi-Nagy T, Deshmane S, Dillner A, et al. Induction of cellular transcription factors in trigeminal ganglia of mice by corneal scarification, herpes simplex type 1 infection, and explantation of trigeminal ganglia. J Virol 1991; 65:4142-52.
42. Mellerick DM, Fraser NW. Physical state of the latent herpes simplex virus genome in mouse model system: evidence suggesting an episomal state. Virology 1987; 158:265-75.
43. Deshmane SL, Fraser NW. During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J Virol 1989;63:943-7.
44. Fraser NW, Block TM, Spivack JG. The latency-associated transcripts of herpes simplex virus: RNA in search of a function. Virology 1992;191:1-8.
45. Dobson AT, Margolis TP, Gomes WA, et al. In vivo deletion analysis of the herpes simplex virus type 1 latency-associated transcript promoter. J Virol 1995;69:2264-70.
46. Nicosia M, Zabolotny JM, Lirette R, et al. The HSV-1 2-kb latency-associated transcript is found in cytoplasm comigrating with ribosomal subunits during productive infection. Virology 1994;204:717-28.
47. Goins WF, Sternberg LR, Croen KD, et al. A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol 1994; 68:2239-52.
48. Johnson PA, Wang MJ, Friedmann T. Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function. J Virol 1994;68:6347-62.
49. Stevens JG, Wagner EK, Devi-Rao GB, et al. RNA complementary to a herpesvirus a gene mRNA is prominent in latently infected neurons. Science 1987; 235:1056-9.
50. Block TM, Spivack JG, Steiner I, et al. A herpes simplex virus type 1 latency-associated transcript mutant reactivates with normal kinetics from latent infection. J Virol 1990;64:3417-26.
51. Lieb DA, Bogard CL, Kosz-Vnenchak M, et al. A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. J Virol 1989;63:2893-900.
52. Krause PR, Stanberry LR, Bourne N, et al. Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med 1995;181:297-306.
53. Bloom DC, Devi-Rao GB, Hill JM, et al. Molecular analysis of herpes simplex virus type 1 during epinephrine-induced reactivation of latently infected rabbits in vivo. J Virol 1994;68:1283-92.
54. Hill JM, Sedarti F, Javier RT, et al. Herpes simplex virus latent phase transcription facilitates in vivo reactivation. Virology 1990;174:117-25.
55. Trousdale MD, Steiner I, Spivack JG, et al. In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model. J Virol 1991;65:6989-93.
56. Cook SD, Paveloff MJ, Doucet JJ, et al. Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants. Invest Ophthalmol Vis Sci 1991;32:1558-61.
57. Block TM, Deshmane S, Masonis J, et al. An HSV LAT null mutant reactivates slowly from latent infection and makes small plaques on CV-1 monolayers. Virology 1993;192:618-30.
58. Deshmane SL, Nicosia M, Valyi-Nagi T, et al. An HSV-1 mutant lacking the LAT TATA element reactivates normally in explant cocultivation. Virology 1993;196:868-72.
59. Natarajan R, Deshmane S, Valyi-Nagy T, et al. A herpes simplex virus type 1 mutant lacking the ICPO introns reactivates with normal efficiency. J Virol 1991;65:5569-73.
60. Harbour DA, Hill TJ, Blyth WA. Recurrent herpes simplex in the mouse: inflammation in the skin and activation of virus in the ganglia following peripheral stimulation. J Gen Virol 1983;64:1491-8.
61. Rooney JF, Bryson Y, Mannix ML, et al. Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet 1991;338:1419-22.
62. Kurane I, Tsuchiya Y, Sekizawa T, et al. Inhibition by indomethacin of in vitro reactivation of latent herpes simplex virus type 1 in murine trigeminal ganglia. J Gen Virol 1984;65:1665-74.
63. Cherrick HM, Li KK, Li SL, et al. Effect of ibuprofen on the in vitro and in vivo reactivation of latent HSV-1. Oral Surg Oral Med Oral Pathol 1992;73:321-7.
64. Harbour DA, Blyth WA, Hill TJ. Prostaglandins enhance spread of herpes simplex virus in cell cultures. J Gen Virol 1978;41:87-95.
65. Baker DA, Thomas J, Epstein J, et al. The effect of prostaglandins on the multiplication and cell-to-cell spread of herpes simplex virus type 2 in vitro. Am J Obstet Gynecol 1982;144:346-9.
66. 2 and interferon on the multiplication of herpes simplex virus type 1 in human lymphoid cells. Antiviral Res 1990;14:161-72.
67. Wachsman M, Aurelian L, Burnett JW. The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections. Br J Dermatol 1990;123:375-80.
68. Bratcher DF, Harrison CJ, Bourne N, et al. Effect of indomethacin on ultraviolet radiation-induced recurrent herpes simplex virus disease in guinea pigs. J Gen Virol 1993;74:1951-4.
69. Alberts B, Bray D, Lewis J, et al, editors. Molecular biology of the cell. New York: Garland Publishing, 1994:740-1.
70. Lieb DA, Nadeau KC, Rundle KC, et al. The promoter of the latency-associated transcripts of herpes simplex virus type 1 contains a functional cAMP-response element: role of the latency-associated transcripts and cAMP in reactivation of viral latency. Proc Natl Acad Sci U S A 1991;88:48-52.
71. Wheatley SC, Dent CL, Wood JN, et al. Elevation of cyclic AMP levels in cell lines derived from latently infectable sensory neurons increases their permissivity for herpes virus infection by activating the viral immediate-early 1 gene promoter. Mol Brain Res 1992;12:149-54.
72. Deb SP, Deb S, Brown DR. Cell-type-specific induction of the UL9 gene of HSV-1 by cell signalling pathway. Biochem Biophys Res Commun 1994;205:44-51.
73. Rader KA, Ackland-Berglund CE, Miller JK, et al. In vivo characterization of site-directed mutations in the promoter of the herpes simplex virus type 1 latency-associated transcripts. J Virol 1993;74:1859-69.
74. Ackland-Berglund C, Davido DJ, Lieb DA. The roles of the cAMP-response element and TATA box in expression of the herpes simplex virus type 1 latency-associated transcripts. Virology 1995;210:141-57.
75. Smith RL, Pizer LI, Johnson Jr EM, et al. Activation of second-messenger pathways reactivates latent herpes simplex virus in neuronal cultures. Virology 1992;188:311-8.
76. Rodriguez A, De La Maza MS, Missry J, et al. The role of cyclic nucleotide mediators in latency and reactivation of HSV-1 infected neuroblastoma cells. Eye 1991;5:627-35.
77. Siegel D, Golden E, Washington AE, et al. Prevalence and correlates of herpes simplex infections: the population-based AIDS in multiethnic neighborhoods study. JAMA 1992;268:1702-8.
78. Kulhanjian JA, Soroush V, Au DS, et al. Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med 1992;326:916-20.
79. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
80. Corey L. Herpes simplex virus infections during the decade since the licensure of acyclovir. J Med Virol 1993; (suppl 1):7-12.
81. Ashley R, Cent A, Maggs V, et al. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus type 1 and 2. Ann Intern Med 1991; 115:520-6.
82. Ashley R. Laboratory techniques in the diagnosis of herpes simplex infection. Genitourin Med 1993;64:174-83.
83. Moore DE, Ashley RL, Zarutske PW, et al. Transmission of genital herpes by donor insemination. JAMA 1989; 261:3441-3.
84. Holmberg S, Stewart JA, Gerber AR, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988;259:1048-50.
85. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral isolation procedures. N Engl J Med 1992;326:1533-9.
86. Ross JD, Smith IW, Elton RA. The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978-1991. Genitourin Med 1993;69:381-3.
87. Tayal SC, Pattman RS. High prevalence of herpes simplex virus type 1 in female anogenital herpes simplex in Newcastle upon Tyne 1983-92. Int J STD AIDS 1994;5:359-61.
88. Zirn JR, Tompkins SD, Huie C, et al. Rapid detection and distinction of cutaneous herpesvirus infections by direct immunofluorescence. J Am Acad Dermatol 1995;33: 724-8.
89. Nahass GT, Goldstein BA, Zhu WY, et al. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicellazoster infections. JAMA 1992;268:2541-4.
90. Weston WL, Brice SL, Jester JD, et al. Herpes simplex virus in childhood erythema multiforme. Pediatrics 1992;89:32-4.
91. Penneys NS, Goldstein B, Nahass GT, et al. Herpes simplex virus DNA in occult lesions: demonstration by the polymerase chain reaction. J Am Acad Dermatol 1991;24:689-92.
92. Cone RW, Hobson AC, Brown Z, et al. Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA 1994; 272:792-6.
93. Prober CG, Hensleigh PA, Boucher FD, et al. Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med 1988;318:887-91.
94. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324:1247-52.
95. Gibson JJ, Hornung CA, Alexander GR, et al. A cross-sectional study of herpes simplex types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis 1990;162:306-12.
96. Kinghorn GR. Epidemiology of genital herpes. J Int Med Res 1994;22(suppl 1):14A-23A.
97. Cowan FM, Johnson AM, Ashley R, et al. Antibody to herpes simplex virus type 2 as serologic marker of sexual lifestyle in populations. BMJ 1994;309:1325-9.
98. Forsgren M, Skoog E, Jeansson S, et al. Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969,1983, and 1989: implications for STD epidemiology. Int J STD AIDS 1994;5:113-6.
99. Cates Jr W, Hinman AR. Sexually transmitted diseases in the 1990's [editorial]. N Engl J Med 1991;325:1368-70.
100. Kohl S. Role of antibody-dependent cellular cytotoxicity in neonatal infection with herpes simplex virus. Rev Infect Dis 1991;13(suppl 11):S950-2.
101. Gibbs RS, Mead PB. Preventing neonatal herpes: current strategies [editorial]. N Engl J Med 1992;326:946-7.
102. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847-54.
103. Koelle DM, Benedetti J, Langenberg A, et al. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992;116:433-7.
104. Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and asymptomatic genital herpes infections. N Engl J Med 1995;333:770-5.
105. Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995;123:845-7.
106. Whitley RJ, Gnann Jr JW. Acyclovir: a decade later. N Engl J Med 1992;327:782-9.
107. Balzarini J, Bohman C, Walker RT, et al. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol Pharmacol 1994;45:1253-8.
108. Memar OM, Tyring SK. Antiviral agents in dermatology: current status and future prospects. Int J Dermatol 1995;34:597-606.
109. Sasadeusz JJ, Sacks SL. Systemic antivirals in herpesvirus infections. Dermatol Clin 1993;11:171-85.
110. Furman PA, St. Clair MH, Spector Y. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem 1984;259:9575-9.
111. Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase: mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989;264:7405-11.
112. Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind, placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 1984; 252:1147-51.
113. Bryson YJ, Dillon M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir: a randomized double-blind controlled trial in normal subjects. N Engl J Med 1983;308:916-21.
114. Reichman RC, Badjer GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984;251:2103-7.
115. Nilson AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982;2:571-3.
116. Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection: a multicenter double-blind trial. JAMA 1988;260:201-6.
117. Goldberg LH, Kaufman R, Kurte T, et al. Long-term suppression of recurrent herpes with acyclovir. Arch Dermatol 1993;129:582-7.
118. Mostow SR, Mayfield JL, Marr J, et al. Suppression of recurrent genital herpes with single daily dosages of acyclovir. Am J Med 1988;85(suppl 2A):30-3.
119. Mindel A, Faherty A, Carney O, et al. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988;1:926-8.
120. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. Ann Intern Med 1993;118:268-72.
121. Kaplowitz LG, Baker D, Gelb L, et al. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. JAMA 1991;265:747-51.
122. Fife K, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir: acyclovir study group. J Infect Dis 1994;169: 1338-41.
123. Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
124. DeMiranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983;12(suppl B):29-37.
125. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drag valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
126. Burnette TC, DeMiranda P. Metabolic disposition of the acyclovir prodrag valaciclovir in the rat. Drug Metab Dispos 1994;22:60-4.
127. Pottage JC, Kessler HA. Herpes simplex viras resistance to acyclovir: clinical relevance. Infect Agents Dis 1995;4:115-24.
128. Kost RG, Hill EL, Tigges M, et al. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993;329:1777-82.
129. Talarico CL, Phelps WC, Biron KK. Analysis of the thymidine kinase gene from acyclovir-resistant mutants of the varicella-zoster virus isolated from patients with AIDS. J Virol 1993;67:1024-33.
130. Wucox CL, Crnic LS, Pize LI. Replication, latent infection and reactivation in neuronal culture with a herpes simplex virus thymidine kinase-negative mutant. Virology 1992;187:348-52.
131. VereHodge RA. Famciclovir and penciclovir: the mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993;4:67-84.
132. Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993;37:2241-3.
133. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993;4(suppl 1): 47-55.
134. VereHodge RA, Cheng YC. The mode of action of penciclovir. Antiviral Chem Chemother 1993;4(suppl 1):13-24.
135. Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36:2747-57.
136. Tyring S, Barbarash RA, Nahlick JE, et al. Famciclovir for the treatment of acute herpes zoster and postherpetic neuralgia. Ann Intern Med 1995;123:89-96.
137. Weinberg A, Bate BJ, Masters HB, et al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 1992;36:2037-8.
138. VereHodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989;33:223-9.
139. Field HJ, Tewari D, Sutton D, et al. Comparison of efficacy of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob Agents Chemother 1995;39:1114-9.
140. Field HJ, Thackray AM. The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1. Antiviral Chem Chemother 1995;6:210-6.
141. Bacon TH, Schinazi RF. An overview of the further evaluation of penciclovir against herpes simplex virus and varicella-zoster virus in cell culture highlighting contrasts with acyclovir. Antiviral Chem Chemother 1993;4(suppl 1):25-36.
142. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994;38:2454-7.
143. Boyd MR, Safrin S, Kern ER. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother 1993;4(suppl 1):3-11.
144. Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med 1992;92(suppl 2A):3S-7S.
145. Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992:92(suppl 2A):30S-35S.
146. Aduma P, Connelly MC, Srinivas S, et al. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol 1995;47:816-22.
147. DeClercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother 1993;32(suppl A):121-32.
148. DeClercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv Virus Res 1993;42:1-53.
149. Ho HT, Woods KL, Bronson JJ, et al. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl] cytosine. Mol Pharm 1992;41:197-202.
150. DeClercq E. Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues. Int J Immunopharmacol 1991;13(suppl 1):91-8.
151. Yang H, Datema R. Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy) propyl] cytosine against herpes simplex virus 2 infections in mice. Antimicrob Agents Chemother 1991;35:1596-600.
152. DeClercq E, Holy A. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine in various models of herpes simplex virus infection in mice. Antknicrob Agents Chemother 1991;35:701-6.
153. Bravo FJ, Stanberry LR, Kier AB, et al. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Res 1993;21:59-72.
154. Flores-Aguilar M, Huang JS, Wiley CA, et al. Long-acting therapy of viral retinitis with (S)-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. J Infect Dis 1994; 169:642-7.
155. Besen G, Flores-Aguilar M, Assil KK, et al. Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC. Arch Ophthalmol 1995;113:661-8.
156. Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994;170:570-2.
157. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HP-MPC). Clin Infect Dis 1994;18:570-8.
158. Snoeck R, Andrei G, DeClercq E, et al. A new topical treatment for resistant herpes simplex infections. N Engl J Med 1993;329:968-9.
159. Snoeck R, Van Ranst M, Andrei G, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl J Med 1995; 333:943-4.
160. Gordon YJ, Romanowski EG, Araullo-Cruz T. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes hearing of dendritic keratitis in the New Zealand rabbit ocular model. Cornea 1994;13:516-20.
161. Roizman B. Introduction: objectives of herpes simplex virus vaccines seen from a historical perspective. Rev Infect Dis 1991;13(suppl 11):S892-4.
162. Stanberry LR. Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol 1995;3:244-7.
163. Langenberg AG, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann Intern Med 1995;122: 889-98.
164. Morein B, Merza M. Vaccination against herpesviruses: Fiction or reality? Scand J Infect Dis 1991;78(suppl): 110-8.
165. Rajcani J, Sabo A, Mucha V, et al. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation. Acta Virol 1995;39:37-49.
166. Nesburn A, Burke RL, Ghiasi H, et al. Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J Virol 1994;68: 5084-92.
167. Ghiasi H, Wechsler SL, Kaiwar R, et al. Local expression of tumor necrosis factor a and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1. Virol 1995;69:334-40.
168. Narang HK. Efficacy of herpes vaccine and acyclovir (ACV) in a rabbit model following intraocular inoculation of herpes simplex virus. J Chemother 1995;7:210-5.
169. Cohen MS. HIV and sexually transmitted diseases: the physician's role in prevention. Postgrad Med 1995; 98:52-8.
170. Burke RL. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. Rev Infect Dis 1991;13(suppl 11):S906-11.
171. Burke RL, Goldbeck C, Ng P, et al. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 1994;170:1110-9.
172. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343:1460-3.
173. Hazama M, Mayumi-Aono A, Asakawa N, et al. Adjuvant-independent enhanced immune response to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2. Vaccine 1993;11:629-36.
174. Bernstein DI, Harrison CJ, Tepe ER, et al. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs. Vaccine 1995;13:72-6.
175. Rooney JF, Wohlenberg CR, Notkins AL. In: Ciardi, editor. Genetically engineered vaccines. New York: Plenum Press, 1992:183-9.
176. Johnson DC. Adenovirus vectors as potential vaccines against herpes simplex virus. Rev Infect Dis 1991;13 (suppl 11):S912-6.
177. Gallichan WS, Johnson DC, Graham FL, et al. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes virus glycoprotein B. J Infect Dis 1993;168:622-629.
178. Heineman TC, Connelly BL, Bourne N, et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995; 69:8109-13.
179. Bourne N, Stanberry LR, Bernstein DI, et al. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996;173:800-7.
180. Nguyen LH, Knipe DM, Finberg RW. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 1992;66:7067-72.
181. McLean CS, Erturk M, Jennings R, et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994;170:1100-9.
182. Farrell HE, McLean CS, Harley C, et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 1994;68:927-32.